GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hybio Pharmaceutical Co Ltd (SZSE:300199) » Definitions » Total Long-Term Liabilities

Hybio Pharmaceutical Co (SZSE:300199) Total Long-Term Liabilities : ¥779.7 Mil (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Hybio Pharmaceutical Co Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Hybio Pharmaceutical Co's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was ¥779.7 Mil.

Hybio Pharmaceutical Co Total Long-Term Liabilities Historical Data

The historical data trend for Hybio Pharmaceutical Co's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hybio Pharmaceutical Co Total Long-Term Liabilities Chart

Hybio Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,256.47 1,514.60 1,166.34 1,070.54 986.63

Hybio Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,188.19 1,176.84 1,101.06 986.63 779.66

Hybio Pharmaceutical Co Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Hybio Pharmaceutical Co Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Hybio Pharmaceutical Co's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Hybio Pharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hybio Pharmaceutical Co Ltd (SZSE:300199) » Definitions » Total Long-Term Liabilities
Comparable Companies
SHSE:600993 SHSE:600422 SHSE:600129 SHSE:603456 SZSE:002675 SHSE:600216 SZSE:300119 SZSE:002317 SHSE:600211 SHSE:600285 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
N/A
Address
4th Floor, Office Building, Hanyu Biomedical Park, Middle District, High-tech Industrial Park, Nanshan District, Guangdong Province, Shenzhen, CHN, 518057
Website
http://www.hybio.com.cn
Hybio Pharmaceutical Co Ltd is engaged in manufacturing and sale of peptide products. The company's peptide finished dosage products include digestive system agents, immune modulators, hormone and endocrine modulators, antiviral agents, and hemostatic products. It also provides peptide CRO and CMO services, as well as API products.
Executives
Ceng Shao Gui Director
Ceng Shao Bin Director
Ceng Shao Qiang Director
Zhu Wen Feng Directors, Directors, and Executives
Tao An Jin Executives
Wei Hong Executives
Yuan Jian Cheng Directors, executives
Liu Jian Executives
Yang Jun Executives
Executives
Zhu Ning Supervisors
Yang Chun Hai Supervisors
Cai Lei Directors, executives

Hybio Pharmaceutical Co Headlines

No Headlines